| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
Baicalein (0-200 μM, 24 hours) can lower the levels of TNF-α and iNOS mRNA expression and decrease NO generation in LPS-activated RAW264.7 cells [1]. HT1080 is inhibited by baicalein (0-50 μM, 24 hours). In HT1080 cells, the expression of MMP-2, -9, and -14 as well as the activation of NF-κB are inhibited by scutellarein (0-50 μM, 24 hours) [3]. DPPH, ABTS+·, and ·OH have scavenging capabilities for baicalein (IC50 values of 16.84 μM, 3.00 μM, and 0.31 mM, correspondingly) [4].
|
|---|---|
| ln Vivo |
In an HFD animal model, baicalein (50 mg/kg in diet for 16 weeks) demonstrated hepatoprotective, lipid-lowering, and anti-stress properties [2]. Baicalein, at doses of 50 and 500 mg/kg, controls the formation of tumors in the HT108 xenograft mouse model [3]. Neuronal damage can be mitigated and the neck's brain structure preserved by scutellarein (0–1.40 mmol/kg, neck) [5].
|
| Animal Protocol |
Animal/Disease Models: HFD mice [2]
Doses: 50 mg/kg Route of Administration: In diet, 16 weeks Experimental Results: diminished lipid accumulation and inflammatory factor levels in the liver. Lost weight. |
| References |
[1]. Sung NY, et al. Scutellarein Reduces Inflammatory Responses by Inhibiting Src Kinase Activity. Korean J Physiol Pharmacol. 2015 Sep;19(5):441-9.
[2]. Lin Y, et al. Novel anti-obesity effect of scutellarein and potential underlying mechanism of actions. Biomed Pharmacother. 2019 Sep;117:109042. [3]. Shi X, et al. Scutellarein inhibits cancer cell metastasis in vitro and attenuates the development of fibrosarcoma in vivo. Int J Mol Med. 2015 Jan;35(1):31-8. [4]. Qian LH, et al. Synthesis and bio-activity evaluation of scutellarein as a potent agent for the therapy of ischemic cerebrovascular disease. Int J Mol Sci. 2011;12(11):8208-16. [5]. Tang H, et al. Neuroprotective effects of scutellarin and scutellarein on repeatedly cerebral ischemia-reperfusion in rats. Pharmacol Biochem Behav. 2014 Mar;118:51-9. |
| Molecular Formula |
C15H10O6
|
|---|---|
| Molecular Weight |
286.2363
|
| Exact Mass |
286.05
|
| Elemental Analysis |
C, 62.94; H, 3.52; O, 33.54
|
| CAS # |
529-53-3
|
| Related CAS # |
529-53-3
|
| Appearance |
Solid powder
|
| SMILES |
C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O)O
|
| InChi Key |
JVXZRQGOGOXCEC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10O6/c16-8-3-1-7(2-4-8)11-5-9(17)13-12(21-11)6-10(18)14(19)15(13)20/h1-6,16,18-20H
|
| Chemical Name |
5,6,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one
|
| Synonyms |
Scutellarein; 4',5,6,7-Tetrahydroxyflavone
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~57 mg/mL (~199.1 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4936 mL | 17.4679 mL | 34.9357 mL | |
| 5 mM | 0.6987 mL | 3.4936 mL | 6.9871 mL | |
| 10 mM | 0.3494 mL | 1.7468 mL | 3.4936 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
